E
Can-Fite BioPharma Ltd. CANF
$1.47 -$0.04-2.65%
Recommendation
Sell
Prev Close
$1.47
Volume
79,481
Avg Vol (90D)
405,943
Market Cap
$15.93M
Dividend & Yield
--
52-Week Range
$1.29 - $4.69
P/E (TTM)
--
EPS (TTM)
-$0.0033
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
3/24/2025 - Globe Newswire
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
3/20/2025 - Globe Newswire
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
3/19/2025 - Globe Newswire
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
3/18/2025 - Globe Newswire
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
3/3/2025 - Globe Newswire
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
2/18/2025 - Globe Newswire
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25
2/10/2025 - Globe Newswire
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
2/5/2025 - Globe Newswire
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
1/27/2025 - Globe Newswire
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson
12/30/2024 - Globe Newswire
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug
12/4/2024 - Globe Newswire
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11/11/2024 - Globe Newswire
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
11/4/2024 - Globe Newswire
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
10/18/2024 - Globe Newswire
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
10/9/2024 - Globe Newswire
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29
10/7/2024 - Globe Newswire
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
9/24/2024 - Globe Newswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
9/16/2024 - Globe Newswire
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
8/29/2024 - Globe Newswire
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
8/8/2024 - Globe Newswire
Can-Fite Provides Namodenoson Patent Update
7/29/2024 - Globe Newswire
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
7/17/2024 - Globe Newswire
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
7/11/2024 - Globe Newswire
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
7/1/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$5.92M
Total Debt (Q)
$57.00K
Total Liabilities (Q)
$3.44M
Book Value Per Share (Q)
$0.0015
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, August 29, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
1.39
7-Day Total Return
-4.55%
30-Day Total Return
-16.48%
60-Day Total Return
-6.37%
90-Day Total Return
-25.00%
Year to Date Total Return
-17.88%
1-Year Total Return
-37.45%
2-Year Total Return
-31.30%
3-Year Total Return
-88.15%
5-Year Total Return
-90.70%
52-week Low
Dec 04, 2024 - $1.29
52-week High
Jul 22, 2024 - $4.69
Valuation
Market Cap
$15.93M - Nano Cap
Enterprise Value
$11.18M
Price/Sales (TTM)
7,350.00
Price/Book (Q)
980.00
Dividends and Shares
Shares Outstanding
1.82B
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.canfite.com
Phone Number
972 3 924 1114
Address
26 Ben Gurion Street
Ramat Gan, 5257346
Country
Israel
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and... more
AMEX 04/04/2025 3:59PM Eastern Quotes delayed
Weiss Ratings